NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a parad...
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
About this item
Full title
Author / Creator
Publisher
Germany: Springer Nature B.V
Journal title
Language
English
Formats
Publication information
Publisher
Germany: Springer Nature B.V
Subjects
More information
Scope and Contents
Contents
There is an urgent need to improve the pharmacotherapy of schizophrenia despite the introduction of important new medications. New treatment insights may come from appreciating the therapeutic implications of model psychoses. In particular, basic and clinical studies have employed the N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, ketam...
Alternative Titles
Full title
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_75751709
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_75751709
Other Identifiers
ISSN
0033-3158
E-ISSN
1432-2072
DOI
10.1007/s00213-003-1582-z
